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Stroke continues to be one of the leading causes of mortality and morbidity worldwide. 
Restoration of cerebral blood flow by recombinant plasminogen activator (rtPA) with or 
without mechanical thrombectomy is considered the most effective therapy for rescuing brain 
tissue from ischaemic damage, but this requires advanced facilities and highly skilled 
professionals, entailing high costs, thus in resource-limited contexts urokinase plasminogen 
activator (uPA) is commonly used as an alternative. This literature review summarises the 
existing studies relating to the potential clinical application of uPA in ischaemic stroke patients. 
In translational studies of ischaemic stroke, uPA has been shown to promote nerve regeneration 
and reduce infarct volume and neurological deficits. Clinical trials employing uPA as a 
thrombolytic agent have replicated these favourable outcomes and reported consistent 
increases in recanalisation, functional improvement, and cerebral haemorrhage rates, similar to 
those observed with rtPA. Single-chain zymogen pro-urokinase (pro-uPA) and rtPA appear to 
be complementary and synergistic in their action, suggesting that their co-administration may 
improve the efficacy of thrombolysis without affecting the overall risk of haemorrhage. Large 
clinical trials examining the efficacy of uPA or the combination of pro-uPA and rtPA are 
desperately required to unravel whether either therapeutic approach may be a safe first-line 
treatment option for patients with ischaemic stroke. In light of the existing limited data, 
thrombolysis with uPA appears to be a potential alternative to rtPA-mediated reperfusive 
treatment due to its beneficial effects on the promotion of revascularisation and nerve 
regeneration. 





Stroke is defined as an acute neurological dysfunction lasting more than 24 hours, attributed to 
cerebrovascular aetiology. In general, it is classified into ischaemic and haemorrhagic types. 
Ischaemic stroke is a focal cerebral infarction causing an episode of neurological deterioration, 
which represents around 85% of stroke incidents. Haemorrhagic stroke is defined as the rapid 
development of neurological dysfunction, attributed to focal collection of blood in brain 
parenchyma or ventricular system that is not caused by trauma, which accounts for the 
remaining 15% of strokes (Hisham and Bayraktutan 2013; Sacco et al. 2013). 
The latest Global Burden Disease (GBD) data showed that stroke is the third leading cause of 
death and disability worldwide (Kyu et al. 2018; Roth 2018). In the UK, more than 100,000 
people suffer from stroke each year, and nearly two-thirds of stroke survivors leave hospital 
with a disability (Stroke Association 2018). In addition, stroke costs almost £9 billion every 
year in health and societal care, accounting for about 5% of net UK National Health Service 
costs (Saka et al. 2009). 
Recombinant tissue plasminogen activator (rtPA) has been approved by US Food and Drug 
Administration (FDA) and European Medicines Agency (EMEA) as the only thrombolytic 
drug that can be used in ischaemic stroke. However, due to high costs, extremely short 
therapeutic window (<4.5 hours), and increased risk of haemorrhage beyond this time point, 
less than 2% of all ischaemic stroke patients globally benefit from this drug (Hacke et al. 2008; 
Powers et al. 2018). Recently, mechanical thrombectomy has made its way into clinical 
practice and extended the therapeutic time window for reperfusion therapy (Turc et al. 2019). 
However, mechanical thrombectomy is only effective in ischaemic stroke stemming from large 
vessel occlusion and can only be performed in clinical units equipped with advanced facilities, 
technical resources, and highly specialised skills in neurology, interventional neuroradiology, 
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and anaesthesiology. Consequently, only very limited number of patients receive this treatment 
(Chia et al. 2016; Leischner et al. 2019).  
In contrast to rtPA, urokinase plasminogen activator (uPA) has received considerably less 
attention in stroke medicine due to its lack of specificity for fibrin, and associated with high 
risk for haemorrhage (Adivitiya and Khasa 2017). Even so, a limited number of studies 
performed with uPA have reported marked improvements in recanalisation and neurological 
outcomes similar to those achieved with treatments with rtPA (Ogawa et al. 2007; Wang et al. 
2017). Furthermore, as uPA is significantly cheaper than rtPA, it is widely used in developing 
countries as the mainstay thrombolytic agent for acute ischaemic stroke (Dong et al. 2017; Lee 
et al. 2012; Misra et al. 2011). Therefore, further investigation is urgently needed to reveal the 
actual benefit and safety profile of uPA. If uPA is beneficial and safe for ischaemic stroke 
patients, its use should be disseminated and promoted worldwide. Conversely, if it is harmful, 
the current application of uPA as a cheap stop-gap in resource-scarce healthcare systems should 
be stopped.   
1.1. Thrombus formation 
Thrombus formation involves a highly complex process, including breach of endothelial cells, 
activation of platelets, and the coagulation system. In response to endothelial injury, collagen 
and tissue factor are exposed to blood flow (Figure 1). Exposed collagen binds to circulating 
von Willebrand factor (vWF), which subsequently binds to platelet through GP1b-IX-V 
receptor, leading to the formation of the collagen-vWF-GP1b-IX-V axis, a key step for the 
initial attachment of platelets (Furie and Furie 2008). However, this axis does not generate 
stable platelet adhesion, rather it decreases the velocity of the flowing platelets. Consequently, 
this initial platelet adhesion provides specific collagen receptors on the platelet surface 
(Glycoprotein VI, GPVI), which induce cellular activation and subsequent release of various 
platelet agonists, notably thromboxane (TxA2) and adenosine diphosphate (ADP), which then 
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generate thrombin (Nieswandt et al. 2011). Thrombin in turn activates protease-activated 
protein (PAR) to further activate platelets (De Candia 2012). Platelet activation signalling 
events trigger functional upregulation of GPIIb/IIIa, which subsequently mediates mass 
aggregation of platelets through binding to fibrinogen and vWF, thereby cross-linking the 
activated platelet and stabilising the growing platelet plug (Thomas and Storey 2015).  
Alongside this, tissue factor induced by endothelial cell injury triggers a secondary pathway 
whereby tissue factor binds to circulating FVIIa, forming tissue factor-FVIIa complex (also 
called binary complex), which in turn activates FX to FXa, whereby it converts FV into FVa. 
In the presence of Ca2+, FVa and FXa convert prothrombin to thrombin. As mentioned above, 
thrombin plays a central step in thrombus formation by stabilising the platelet plugs and by 
converting fibrinogen to fibrin monomers (Chapin and Hajjar 2015; Riddel et al. 2007). 
1.2. Thrombolytics 
Since thrombolytics degrade cross-links between fibrin networks and restore blood flow to 
penumbra, they represent the primary drug option for ischaemic stroke patients (Ramos-Cabrer 
et al. 2011). According to their fibrin specificity, thrombolytics are divided into two categories, 
namely fibrin-specific agents, which prevent systemic fibrinolysis; and nonfibrin-specific 
drugs. Table 1 summarises the characteristics of such drugs. 
2. Urokinase-plasminogen activator 
uPA is secreted as an inactive single chain precursor (pro-uPA) with high fibrin specificity. 
Proteolytic cleavage by plasmin or plasma kallikrein at Lys158-Ile159 peptide bond converts 
pro-uPA into high molecular weight uPA (54kDa) which in turn is converted to low molecular 
weight uPA (32kDa ) by sustained proteolytic activity by plasmin (Figure 1) (Poliakov et al. 
2001). Once generated, uPA, a member of the serine protease protein family, converts 
plasminogen into plasmin by binding to its receptor (uPAR) on the cell surface (Blasi and 
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Carmeliet 2002). Other than being instrumental in plasminogen activation, the uPA-uPAR 
binding also promotes the degradation of the extracellular matrix, a major event that underlies 
tumour progression and metastasis (Mahmood et al. 2018). Recent studies proving soluble 
uPAR as an important independent predictor for cardiovascular events in patients with first 
AMI and all-cause mortality at five-year after ischaemic strokes, indicating the importance of 
this particular receptor and the overall uPA activity in ischaemic vascular events (Onatsu et al. 
2017; Wlazel et al. 2019).  
 In contrast to tPA, uPA has lower affinity for plasminogen and does not require fibrin as a 
cofactor. Similar to tPA, uPA is rapidly neutralised in circulation by plasminogen activator 
inhibitors (Chapin and Hajjar 2015). It is noteworthy that pro-uPA can directly activate 
plasminogen without being transformed into uPA (Pannell and Gurewich 1986). However, as 
plasmin-mediated conversion of pro-uPA to uPA negates its fibrin-specificity, a single site 
mutant (M5) of native pro-uPA, resistant to conversion into uPA, has been designed (Tomasi 
et al. 2011). 
2.1. uPA in neuroreparation  
Incomplete neurological recovery of uPA- (uPA-/-) or uPAR- (uPAR-/-) deficient mice 
subjected to middle cerebral artery occlusion (MCAo) confirms the pivotal role of uPA-uPAR 
pathway in neuroreparation. Restoration of neurological recovery by immediate intra-arterial 
administration of recombinant uPA to mice deficient in uPA-/-, but not uPAR-/-, indicates that 
the presence (and therefore binding) of uPA to uPAR is a prerequisite for functional 
improvement after a cerebral ischaemic injury (Wu et al. 2014). In support of this notion, uPA-
uPAR binding has been coupled to successful repair of damage to actin cytoskeleton in post-
synaptic compartment, and therefore is implicated in the recovery of synaptic contacts 
destructed by ischaemic stroke (Merino et al. 2018). In addition to this, attribution of synaptic 
recovery in ischaemic brain to a crosstalk between neuronal uPA and astrocytic uPAR has 
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further corroborated the reparative role of uPA-uPAR pathway (Diaz et al. 2017). Enhanced 
expression of uPAR and its association with uPA in injured axons has been shown to promote 
axonal regeneration, by triggering membrane recruitment and activation of 1 integrin through 
a mechanisms involving small GTPase Rac1, suggesting that the uPA-uPAR-Rac1 system may 
be a potential target for induction of axonal recovery in ischaemic stroke (Merino et al. 2017; 
Semina et al. 2016).  
Contrary to these restorative effects, increased activity of uPA in various experimental settings 
mimicking ischaemic stroke appears to impair the integrity and function of an in vitro model 
of human blood-brain barrier (BBB). Since BBB disruption represents the main cause of death 
within the first week after stroke (Giraud et al. 2015; Jha 2003), its association with uPA-uPAR 
system is of high clinical importance (Lasek-Bal et al. 2019). To this end, increased availability 
and activation of calcium and protein kinase C- have been shown to account for ischaemia-
induced uPA release, which in turn evokes BBB dysfunction through cytoskeletal 
reorganisation of BBB-forming cells and concomitant activations of NADPH oxidase and 
MMP-2 (a basement membrane-degrading enzyme). Changes in cellular architecture induced 
by neuroinflammatory cytokine TNF- or agents that rearrange actin- or tubulin-based 
cytoskeleton have also increased uPA and uPAR expression in other cell lines (Abdullah and 
Bayraktutan 2014; Abdullah and Bayraktutan 2016; Bayraktutan and Jones 1995). Although 
this subject remains to be explored, the concentration of uPA may determine the nature of 
response (i.e., restorative vs. disruptive) subsequently attained. 
2.2. Translational studies  
Treatment with uPA has shown promising results in various animal models of ischaemic stroke, 
including MCAo baboon and cynomolgus monkey model of thromboembolic stroke, as 
evidenced by significant improvements in functional outcome and reductions in infarct 
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volumes compared to placebo-treated animals (Del Zoppo et al. 1986; Susumu et al. 2006). As 
suggested above, the dose of uPA appears to play an important role in its response, in that while 
improving functional outcome, higher doses of uPA also enhance the risk of intracranial 
haemorrhage (ICH). Lower doses of uPA, on the other hand, reduced the occurrence of ICH 
while presenting markedly attenuated (albeit still significant) neurological improvements, 
compared to placebo-treated animals (Shuaib et al. 1998). In addition to these findings, the 
presence of uPA in animal model of myocardial infarction and hind limb muscle enhanced 
angiogenesis, resulting in increased blood flow and tissue protection (Traktuev et al. 2007). 
Similar to uPA, intravenous administration of recombinant pro-uPA to animal models of 
ischaemic stroke also dramatically improved neurological function, comparable to the effects 
generated by rtPA (Hao et al. 2018a; Hao et al. 2018b).  
2.3. Clinical trials 
The majority of clinical trials using uPA for ischaemic stroke are non-randomised controlled 
trials (i.e., single-arm trials), which inevitably cannot attribute the variations observed in 
recanalisation rate, neurological improvement, and incidence of haemorrhagic transformation 
to treatments with uPA, placebo, or natural history of the disease. This wide variation is most 
likely due to factors including the dose of uPA, time window, outcome assessment grading 
system, route of administration, application of mechanical thrombectomy, and differences in 
patients’ baseline demographic and neurological characteristics (e.g., age and neurological 
status at admission). For example, mechanical thrombectomy followed by administration of 
uPA to patients within six hours of symptom onset led to successful recanalisation of patients 
(94.7%) and improved functional outcome (57.9%). Conversely, application of uPA within 7.5 
hours of symptom onset without mechanical thrombectomy led to less than half the sample 
being recanalised (Table 2) (Jahan et al. 1999; Kim et al. 2008). 
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Intra-arterial administration of recombinant pro-uPA to ischaemic stroke patients within the 
first six hours of stroke symptoms in Prolyse in Acute Cerebral Thromboembolism II 
(PROACT II) trial resulted in 40% of patients being classified with a good functional outcome 
(mRS 0-2) at day 90, whereupon the incidence of symptomatic ICH was not statistically 
significant between treatment and control group (Furlan et al. 1999). This result not only 
showed the benefit of recombinant pro-uPA, but also raised the hopes of extending the time 
window from 4.5 to 6 hours. Despite the premature cessation of uPA due to the approval of 
rtPA as the only thrombolytic drug for ischaemic stroke in Japan, Middle Cerebral Artery 
Embolism Local Fibrinolytic Intervention Trial (MELT) also reported excellent functional 
outcome (mRS 0-1) in uPA-treated versus control group. Good functional outcome was still 
more frequent in the treatment arm compared to control group, although this did not reach 
statistical significance (Ogawa et al. 2007). In addition, a recent single-centre prospective study 
revealed that intra-arterial administration of uPA also demonstrated an enormous advantage 
for patients with small branches occlusion, in which the uPA group had higher score of 
National Institute of Health Stroke Scale (NIHSS) on the second day and more frequent good 
functional outcome after 3 months with no increase in rates of ICH. This study is remarkably 
important as intra-arterial reperfusion known to be effective only for large vessel occlusion 
(Shang et al. 2018).  
A meta-analysis involving PROACT, PROACT II, and MELT trials also confirmed that intra-
arterial application of either uPA or pro-uPA is safe and effective in ischaemic stroke patients, 
despite increasing the risk of symptomatic ICH (Fields et al. 2011). An ongoing phase III 
clinical trial investigating the therapeutic efficacy of pro-uPA within 4.5-6 hours 
(NCT03578822) may add further weight to this finding. However, rtPA, at present, remains 
the only FDA-approved agent for ischaemic stroke.  
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2.4. Pro-uPA/uPA versus rtPA 
The first study to compare rtPA and uPA in ischaemic stroke patients showed comparable 
effectivity, safety, and recanalisation rates (Terashi et al. 1990). A subsequent comparative 
analysis of pro-uPA and rtPA in patients with acute myocardial infarction (AMI) demonstrated 
similar rates of patency, reocclusion, and ICH between both treatment groups (Bar et al. 1997).  
Although a retrospective study of patients with vertebrobasilar occlusion showed that rtPA is 
more effective in achieving complete recanalisation compared to uPA, the incidence of 
haemorrhage also appeared to be higher in the rtPA group. It is noteworthy that the higher 
dosages of rtPA and greater volume of thrombus in uPA group may contribute to these results 
(Schulte-Altedorneburg et al. 2007). A recent clinical trial comparing IV alteplase, IV uPA, 
and interventional uPA (i.e., uPA injected to the specific vascular occlusion area via a 
microcatheter) also reported insignificant differences in recanalisation, good prognosis, and 
mortality rates among the three approaches (Wang et al. 2017). Comparative investigation of 
the benefits attained by treatments with pro-uPA, uPA, and rtPA within 4.5 hours is being 
undertaken in a cohort study (NCT02854592, estimated sample size: 4000) and a phase III 
randomised controlled trial (NCT03541668, estimated sample size: 680).  
2.5. Synergism of pro-uPA and rtPA 
Increasing evidence suggests that pro-uPA and tPA may be complementary and synergistic in 
their action, owing to their functional distinction, where tPA acts as an initiator of thrombolysis 
while pro-uPA finishes it (Gurewich 2016). Indeed, once a thrombus is generated, tPA 
catalyses the conversion of plasminogen to plasmin, which ultimately facilitates fibrin 
dissolution, and consequently generates two new plasminogen binding sites on degraded fibrin 
(Oliver et al. 2005). The first of these, a triple carboxy-terminal lysine binding site on the E-
domain of degraded fibrin, promotes a conformational change in plasminogen and allows pro-
uPA to execute its fibrinolytic effect on degraded fibrin, leading to the conversion of pro-uPA 
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to uPA by plasmin. uPA then dissolves the remaining fibrin-bound plasminogen and completes 
the fibrinolysis (Gurewich 2016; Petersen 1997).  
The beneficial effect of this combinatory strategy was evident in the PATENT trial, in which 
over 80% of patients with AMI exhibited complete coronary artery patency within 24 hours 
after receiving a small bolus of tPA (5mg, 5% of the monotherapy dose), followed by a reduced 
dose of pro-uPA infusion (40mg/h for 90 minutes, 50% of the monotherapy infusion rate) 
(Zarich et al. 1995). Interestingly, the patency rate was ~45% in the optimum rtPA trial, 
GUSTO. The mortality rates for PATENT and GUSTO were 1% and 6.3%, respectively 
(Zarich et al. 1995) . Although the PATENT trial presented sophisticated results, combination 
therapy was not approved as the standard treatment, as no follow-up study was provided.  
In case of ischaemic stroke, the efficacy of combining pro-uPA and rtPA is only recently being 
studied in the DUMAS phase II multicentre randomised controlled trial. 
3. Future directions 
Despite increasing the risk of haemorrhage, uPA is widely used as the main thrombolytic drug 
for ischaemic stroke in several countries, due particularly to its low cost (Dong et al. 2017; 
Kleindorfer et al. 2017; Lee et al. 2012; Misra et al. 2011). However, at present there is 
insufficient evidence for the efficacy and the safety profile of this therapy, necessitating larger 
clinical trials to support or dismiss the application of uPA for ischaemic stroke. MELT trial 
remains the largest clinical trial documenting the safety and efficacy of uPA, but in interpreting 
its results, it is important to remember that patients with relatively mild stroke (median 
NIHSS=14) who received mechanical thrombectomy and/or thrombolytic therapy during an 
earlier time window (median time=3.8 hours) were included in this study (Ogawa et al. 2007). 
It is equally important to remember that rtPA and pro-uPA are complementary and synergistic 
in their fibrinolytic action, and their simultaneous application at lower doses is more effective 
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in recanalising occluded vessels in AMI patients than monotherapy, without increasing the risk 
of haemorrhage (Zarich et al. 1995). If replicated, this may be supported as the first-line 
therapeutic option for ischaemic stroke patients. Nevertheless, the disruptive effect of uPA on 
cerebral barrier integrity necessitate uPA dose-rate response investigation and should be 
considered in future trials (Abdullah and Bayraktutan 2016; Rakkar et al. 2014). 
4. Conclusion 
Pre-clinical studies unanimously confirm that, similar to rtPA, uPA degrades fibrin cross-link 
network and restores blood flow. Recent evidence shows that activation of uPA/uPAR system 
contributes to post-ischaemic nerve regeneration through restoration of actin cytoskeleton, 
recovery of post-synaptic compartment, and promotion of axonal regeneration. While 
administration of uPA has been shown to reduce infarct volume and neurological deficit in 
clinical settings, it also appeared to elevate haemorrhagic transformation, a set of findings 
documented with rtPA.  Hence, comparable safety profiles and functional clinical outcomes 
have been reported in studies employing rtPA and uPA after ischaemic strokes.  
Despite increases in data revealing the benefits obtained with uPA treatment, health authorities 
in developed countries are reluctant to consider it as an alternative thrombolytic agent to rtPA. 
However, in developing countries, uPA continues to be used as an alternative agent for 
ischaemic stroke. Therefore, large-scale clinical trials are urgently needed to investigate 
whether uPA is safe and of clinical benefit. If that is the case, the health authorities should 
perhaps consider its use as an alternative around the world enabling an increasing proportion 
of patients receiving early thrombolysis. If not, the current application of uPA as a cheap stop-
gap in resource-scarce healthcare systems ought to be proscribed.   
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Figure 1. Simplified scheme of thrombus formation and mechanism of action of uPA. 
vWF: von Willebrand factor; uPA: urokinase plasminogen activator; pro-uPA: pro-urokinase 
plasminogen activator; GP1b-IX-V: glycoprotein 1b-IX-V; GPVI: glycoprotein VI; PAR: 
protease-activated receptor; Ca2+: calcium; PAI: plasminogen activator inhibitor; FDP: fibrin 
degradation product; GFD: growth factor domain; KD: kringle domain; CD: catalytic serine 
protease domain; HMw-uPA: high molecular weight uPA; LMw-uPA: low molecular weight 
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Table 1. The characteristics of various thrombolytic agents. 
 Streptokinase Urokinase Pro-urokinase tPA 
Molecular weight 
(kDA) 
47 HMw: 54 
LMw: 32 
55 70 











Half-life (min) 18 6-18 3-6 6 
Cost Low Moderate Not known High 
Immunogenicity Yes No No No 
Fibrinogenolytic Very high Moderate Not even at high 
concentration 
Only at high 
concentration 
uPA: urokinase plasminogen activator; pro-uPA: pro-urokinase plasminogen activator; tPA: tissue 













Table 2. Clinical trials using uPA (*) or pro-uPA (**) as potential therapeutic in ischaemic stroke patients.  
Principal Investigator 
(study name where 
available) 
Study Design Key Findings 
Mori et al. (1988)* 
 
o 22 patients 
o Time window: <12 hours 
o Single-arm trial 
o Mechanical disruption: prohibited 
o Immediate recanalisation – 45% of patients, associated with decreased 
infarct volume 
o Symptomatic ICH – 18% of patients  
Jahan et al. (1999)* 
 
o 21 patients 
o Time window: <7.5 hours 
o Single-arm trial 
o Mechanical disruption: prohibited 
o Successful recanalisation – 42% of patients 
o Good functional outcome – 48% of patients. 
o Symptomatic ICH – 38% of patients.  
Gönner et al. (1998)* 
 
o 43 patients 
o Time window: 6 hours 
o Single-arm trial 
o Mechanical disruption: allowed 
o Favourable functional outcomes on day 90 – 61% of patients  
o Symptomatic haemorrhagic – 4.7% of patients  
PROACT (del Zoppo et 
al. 1998)** 
 
o 40 patients 
o Time window: <6 hours 
o Randomised-controlled trial 
o Mechanical disruption: prohibited 
o Higher rates of partial and complete recanalisation and haemorrhagic 
transformation in recombinant pro-uPA vs placebo group  
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Principal Investigator 
(study name where 
available) 
Study Design Key Findings 
PROACT II (Furlan et 
al. 1999)** 
 
o 180 patients 
o Time window: <6 hours 
o Randomised-controlled trial 
o Mechanical disruption: prohibited 
o Good functional outcome in recombinant pro-uPA versus control group 
o Similar rates of mortality and ICH incidence between the two groups 
Arnold et al. (2002)* 
 
o 100 patients 
o Time window: <6 hours 
o Single-arm trial 
o Mechanical disruption: allowed 
o Successful recanalisation – 76% of patients 
o Good functional outcomes on day 90 – 68% of patients 
o Symptomatic ICH – 7% of patients. 
Australian urokinase 
stroke trial (Macleod et 
al. 2005)* 
 
o 16 patients 
o Time window: <24 hours 
o Randomised controlled trial 
o Mechanical disruption: prohibited 
o 4 of 8 patients in the uPA-treated group died 
o 7 of 8 patients in the control group died 
o Good functional outcomes – in all survivors in both groups 
Kim et al. (2008)* 
 
o 19 patients 
o Time window: 3-6 hours 
o Single-arm trial 
o Mechanical disruption: allowed 
o Successful recanalisation – 94.7% of patients 
o Good functional outcome at day 90 – 57.9% of patients 
o symptomatic ICH – 10.5% of patients 
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Principal Investigator 
(study name where 
available) 
Study Design Key Findings 
MELT (Ogawa et al. 
2007)* 
 
o 114 patients 
o Time window: <6 hours 
o Randomised controlled trial 
o Mechanical disruption: allowed 
o Better functional outcome at day 90 in uPA versus control group 
o Higher incidence of haemorrhagic transformation in uPA group  
Chang et al. (2010)* 
 
o 25 patients 
o Time window: <6 hours 
o Single-arm trial 
o Mechanical disruption: allowed 
o Successful recanalisation – 68% of patients  
o Favourable outcome (mRS 0-3) – 36% of patients 
o Symptomatic ICH – 12% of patients  
uPA: urokinase plasminogen activator; pro-uPA: pro-urokinase plasminogen activator; ICH: intracranial haemorrhage; IV: intravenous; mRS: modified 
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